First Patient Enrolled in SELUTION SLR IDE BTK Study
PR96391
LEIPZIG, Germany, June 8, 2022 /PRNewswire=KYODO JBN/ --
The first patient has been enrolled in the FDA IDE BTK (Below-the-Knee)
SELUTION4BTK clinical trial involving SELUTION SLR(TM), MedAlliance's novel
sirolimus-eluting balloon, just one week after receiving IDE approval.
"I am excited to begin an important trial which will establish the evidence
that this novel technology benefit patients suffering from CLTI," commented Dr.
Michael Lichtenberg, Chief of the Angiology Department at the Klinikum
Hochsauerland, Arnsberg, Germany. "So far nothing has worked consistently in
this patient population. The early clinical data from SELUTION SLR registries
are encouraging and I have seen the performance of this new technology in my
routine work. This study is designed to prove that SELUTION SLR is more
effective than the current standard of care in this difficult patient
population."
The start of enrollment in the study follows IDE (Investigational Device
Exemption) approval in the US one week ago. The BTK indication for SELUTION SLR
was granted Breakthrough Device Designation by the FDA in 2019.
The aim of the SELUTION4BTK clinical trial is to demonstrate the superior
efficacy and equivalent safety of SELUTION SLR compared to plain (uncoated)
balloon angioplasty (POBA) in the treatment of BTK arteries in CLTI (Chronic
Limb Threatening Ischemia) patients. The trial is a prospective, multi-center,
single blinded, randomized study.
377 subjects are being randomized 1:1 to either SELUTION SLR or the
control. This is the first study of its kind where 'real world' patients with
CLI (Critical Limb Ischemia) can be included. Patients are being enrolled at
approximately 40 sites across the US, Europe and Asia.
"I am very proud of the MedAlliance team which has been able to initiate
this study so quickly and have the first patient enrolled only a week after
receiving IDE approval," commented Jeffrey B. Jump, MedAlliance Chairman and
CEO. "This is a great achievement and a major milestone for MedAlliance."
SELUTION SLR was awarded CE Mark Approval for the treatment of peripheral
artery disease in February 2020 and for the treatment of coronary artery
disease in May 2020. The US FDA has awarded SELUTION SLR with four breakthrough
designations: for the treatment of atherosclerotic lesions in native coronary
arteries; coronary in-stent restenosis; peripheral below-the-knee and
AV-Fistula indications.
In August 2021, the first of over 3,000 patients was enrolled in a
ground-breaking coronary randomized controlled study comparing SELUTION SLR
with a limus drug-eluting stent [DES]. This is the largest DEB study ever
initiated and has the potential to change medical practice.
MedAlliance's DEB technology involves unique MicroReservoirs made from
biodegradable polymer intermixed with the anti-restenotic drug sirolimus. These
MicroReservoirs provide controlled and sustained release of the drug for up to
90 days1. Extended release of sirolimus from stents has been proven highly
efficacious in both coronary and peripheral vasculatures. MedAlliance's
proprietary CAT™ (Cell Adherent Technology) enables the MicroReservoirs to be
coated onto balloons and adhere to the vessel lumen when delivered via an
angioplasty balloon.
SELUTION SLR is available in Europe and all other countries where the CE
Mark is recognized.
Media Contact:
Richard Kenyon
rkenyon@medalliance.com
+44 7831 569940
About MedAlliance
MedAlliance is a privately-owned medical technology company. It is
headquartered in Nyon, Switzerland, with offices in Germany, Singapore, UK and
USA. MedAlliance specializes in the development of ground-breaking technology
and commercialization of advanced drug device combination products for the
treatment of coronary and peripheral artery disease. For further information
visit: www.medalliance.com
1. Drug concentration evident in MicroReservoirs and tissue – Data on file
at M.A. Med Alliance SA
Photo: https://mma.prnewswire.com/media/1834626/MedAlliance_Image.jpg
Logo: https://mma.prnewswire.com/media/1196864/MedAlliance_Logo.jpg
Source: MedAlliance
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。